AC Immune SA EPS

Mi az AC Immune SA EPS?

A EPS az AC Immune SA - 0.73

Mi a EPS meghatározása?



Az egy részvényre jutó nyereség (EPS) az a társaság nyereségének a része, amely a törzsrészvények minden egyes fennálló részesedéséhez tartozik. A hígításhoz igazodik, és a tizenkét hónap után kiszámítjuk.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

EPS a Health Care szektor a NASDAQ-on cégekben a AC Immune SA -hoz képest

Mit csinál AC Immune SA?

ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor

eps -hoz hasonló cégek AC Immune SA